

SARS-COV-2 antibody prevalence in patients on dialysis in the US in January 2021

Authors:

Shuchi Anand, MD, Department of Medicine (Nephrology), Stanford University
Maria Montez-Rath, PhD, Department of Medicine (Nephrology), Stanford University
Jialin Han, MS, Department of Medicine (Nephrology), Stanford University
LinaCel Cadden, CLS, Ascend Clinical Laboratory
Patti Hunsader, CLS, Ascend Clinical Laboratory
Russell Kerschmann, MD, Ascend Clinical Laboratory
Paul Beyer, MBA, Ascend Clinical Laboratory
Scott D Boyd, MD, PhD, Department of Pathology, Stanford University
Pablo Garcia, MD, Department of Medicine (Nephrology), Stanford University
Mary Dittrich, MD, US Renal Care
Geoffrey A Block, MD, US Renal Care
Julie Parsonnet, MD, Departments of Medicine (Infectious Diseases and Geographic Medicine), and
Epidemiology and Population Health, Stanford University
Glenn M Chertow, MD, Departments of Medicine (Nephrology), and Epidemiology and Population
Health, Stanford University

ABSTRACT

Background: To estimate seroprevalence of SARS-CoV-2 antibodies in the US, the country with the world's largest absolute numbers of COVID19 cases and deaths, we conducted a cross-sectional assessment from a sample of patients receiving dialysis in January 2021.

Methods: We tested remainder plasma of 21,424 patients receiving dialysis through the third-largest US dialysis organization, with facilities located nationwide. We used the Siemens spike protein receptor binding domain total antibody assay to estimate crude SARS-CoV-2 seroprevalence, and then estimated seroprevalence for the US dialysis and adult population by standardizing by age, sex and region. We also compared January 2021 seroprevalence and case-detection rates to that from a similar subsample of patients receiving dialysis who had been tested in July 2020.

Results: Patients in the sample were disproportionately from older age and minority race/ethnic groups. Seroprevalence of SARS-CoV-2 was 18.9% (95% CI: 18.3-19.5%) in the sample, 18.7% (18.1-19.2%) standardized to the US dialysis population, and 21.3% (20.3-22.3%) standardized to the US adult population (range 15.3-20.8% in the Northeast and South respectively). Younger age groups (18-44 years), and persons self-identifying as Hispanic or living in Hispanic neighborhoods, and persons living in the poorest neighborhoods were among the subgroups with the highest seroprevalence (25.9% (24.1-27.8%), 25.1% (23.6-26.4%), 24.8% (23.2-26.5%) respectively). Compared to data from July 2020, we observed diminished variability in seroprevalence by geographic region and urban-rural status. Estimated case detection rate increased from 14% to 23% in July 2020 to January 2021.

Conclusions: A year after the first case of SARS-CoV-2 infection was detected in the US, fewer than one in four adults have evidence of SARS-CoV-2 antibodies. Vaccine roll out to majority minority neighborhoods and poorer neighborhoods will be critical to disrupting the spread of infection.

Funding: Ascend Clinical Laboratories funded remainder-plasma testing.

Introduction

In the year-long period since SARS-CoV-2 case was reported in the US, COVID-19 cases, deaths, and hospitalizations overwhelmed health systems in the country. To date, more than 25 million cases and 500,000 deaths have been attributed to SARS-CoV-2 infection^{1,2}. While in Spring 2020, the most intense burden of disease was experienced in and around the state of New York, nearly all regions in the US including rural areas have recently faced threats to their hospital capacity, with the largest numbers accruing between November and December 2020².

Data continue to support that symptomatic cases represent a fraction of persons infected with SARS-CoV-2³. The vast majority of persons with infection, however, whether asymptomatic or symptomatic, do mount a specific antibody response^{4,6}, with the latest data indicating SARS-CoV-2 receptor binding domain (RBD) IgG antibodies persist for at least four to six months after infection^{4,7,8}. Thus, seroprevalence estimates remain an essential measure of the extent of SARS-CoV-2 community spread.

Following our proposed strategy of performing repeated seroprevalence surveys among patients on dialysis, a population broadly representative of groups susceptible to SARS-CoV-2 infection and among whom routine requirements for monthly laboratories facilitates surveillance⁹, we implemented a cross-sectional seroprevalence analysis in a sample of 21,424 patients on dialysis in the US in January 2021. Our goal was to assess SARS-CoV-2 seroprevalence prior to widespread roll out of COVID19 vaccination. We also tested the persistence of previously observed differences in seroprevalence by region, age, sex, race/ethnicity, and other community-level strata of interest including population density and neighborhood poverty. Finally, to assess for improvements in diagnosis and treatment since our July 2020 and January 2021 timepoints.

Methods

We replicated methods presented previously⁹, including the use of a highly sensitive and specific total RBD total antibody assay on remnant plasma from routine monthly laboratory draws. The primary difference was in the sample population. Previously, samples were obtained from multiple dialysis networks and from patients residing in 46 states. The current sample derived from a single national dialysis network, US Renal Care, the third largest dialysis center in the US with 518 facilities and from patients residing in 43 states. We tested all patients (n=21424) within this single dialysis network in preparation for a longitudinal study being conducted in this network to ascertain response to COVID19 vaccination.

The study received Institutional Review Board Approval from Stanford University.

Assay characteristics

In partnership with a commercial laboratory receiving routine monthly laboratories of patients on dialysis, we tested the remnant plasma of all patients receiving dialysis through US Renal Care. We used the Siemens RBD total antibody (Ig) chemiluminescence assay, which has 100% sensitivity (≥ 14 days post +PCR test) and 99.8% specificity¹⁰.

Statistical analyses

We determined seroprevalence estimates and 95% confidence intervals for the crude (unweighted) sample from January 2021. We then standardized seroprevalence estimates accounting for age, sex, and region, using the distribution of the US dialysis population as available through the United States Renal Data System¹¹ and for the US adult population as available through the 2018 American Community Survey 1-year estimates¹². Next we examined differences in seroprevalence by the following strata: age, sex, region, self-reported race/ethnicity, neighborhood race/ethnicity composition, neighborhood poverty, and urban/rural status⁹.

We also compared data on differences in seroprevalence by patient and neighborhood characteristics and region of residence strata to the observed differences in July 2020. To ensure accurate comparisons, we limited the July 2020 sample to those obtained within US Renal Care (n=11,746 (41%) of 28,503 tested in July, **supplemental Table 1**).

Finally, we compared case detection and infection fatality rates in July 2020 versus January 2021. We computed case detection rates as the proportion of detected cases per 100,000² from a denominator totaling seroprevalence estimates per 100,000 (standardized to the US adult population) and deaths per 100,000 in January 1 2020-June 31 2020, and July 1 2020-December 31 2020 for the July 2020 and January 2021 estimates respectively. We adjusted the numerator of detected cases to reflect adults only using Centers for Disease Control data on proportion of overall cases occurring in adults (~92% in June 2020¹³ and ~89% in December 2020¹⁴). We computed the infection fatality rate as the proportion of deaths per 100,000 from a denominator of seroprevalent persons per 100,000 in the corresponding time periods.

Results

Of the 21,424 persons tested in the first week of January 2021, a majority were men and were older than 65 years of age, similar to the overall US dialysis population (**Table 1**). Although patients resided in a total of 43 states, 33 states contributed >30 patients to the sample. Persons from the South and West regions were modestly overrepresented. Neighborhood race/ethnicity composition closely matched the US dialysis population. Compared to the US adult population, sampled patients were older, more likely male, and more likely to be of non-white race and Hispanic ethnicity.

In January 2021, SARS-CoV-2 RBD seroprevalence estimates were 18.9% (95% CI 18.3, 19.5%) in the sample, 18.7% (18.1, 19.2%) standardized to US dialysis, and 21.3% (20.3, 22.3%) standardized to US adult population respectively (**Table 2**). Younger age groups (18-44 years), and persons self-identifying

as Hispanic or living in Hispanic neighborhoods, and persons living in the poorest neighborhoods were among the subgroups with the highest seroprevalence.

We compared these values to observations from patients within the US Renal Care network tested in July 2020. In this subset in July, the sample, dialysis adjusted and US population adjusted seroprevalence rates were 4.4 (4.0, 4.8), 4.7 (4.3, 5.2), and 5.4 (4.6, 6.2), respectively (**supplemental Table 2**). Relative to July, January 2021 seroprevalences were 2-fold, 4-fold, and 5-fold higher in the Northeast, Midwest, and South and West respectively (**Figure 1**). Regional and rural vs. urban seroprevalences varied less than previously (**supplemental Figure 1**), but striking differences remained by race/ethnicity and poverty. Seroprevalence was 1.7-fold (95% CI 1.6, 1.9) higher among persons living in majority-Hispanic compared to majority-white neighborhoods, and 2.0-fold (95% CI 1.8, 2.3) higher among persons living in neighborhoods with $\geq 30\%$ versus $<10\%$ of residents living in poverty (**Figure 2**).

Discussion

In a January, 2021 nationwide surveillance of SARS-CoV-2 seroprevalence among patients on dialysis, we found that, despite national surges in cases and almost half a million deaths, fewer than one in four US adults had evidence of SARS-CoV-2 antibody. Compared to July 2020, spread of SARS-CoV-2 throughout the US became more uniform across geographic regions, and urban and rural areas. The largest differences in seroprevalences occurred between younger and older age groups, residents of majority Hispanic versus majority white neighborhoods, and residents of poorer versus more affluent neighborhoods. Case detection improved but close to three in four cases remained undiagnosed. Our data emphasize the critical need for prompt, wide-spread vaccination, and ongoing mitigation efforts since on the basis of this seroprevalence evaluation, much of the population still remains vulnerable to SARS-CoV-2 infection.

Few up-to-date data exist on SARS-CoV-2 seroprevalence from countries with high numbers of cases and deaths from COVID19. In the US, the Centers for Disease Control (CDC) implemented a large and

geographically diverse longitudinal sero-surveillance using repeated commercial laboratory testing. Our July seroprevalence estimates were in line with those reported using the CDC strategy.¹⁵ The latest available data from the CDC, however, are from November 2020, prior to the largest surge of cases in the US. Outside of the US, India performed over 15000 home visits in 700 communities testing 29,000 people with plasma nucleocapsid IgG testing between August and September 2020 and estimated seroprevalence of 7% among adults, at a time when the country had recorded roughly six million cases¹⁶. In the UK, the Real-time assessment of Community Transmission (REACT) study mailed lateral flow immunoassays to randomly selected UK residents^{17,18}. This ongoing study has a wide reach (over 350,000 participants reached by fall 2020), amenable to repeat serosurveillance. In the last iteration prior to vaccine roll out, the authors observed a decline in seroprevalence over time possibly due to rapid decay in the qualitative measure of anti-Spike antibody, limiting the study's ability to estimate overall infection rates in the UK¹⁷. Brazilian investigators using blood donor samples in Manaus, Brazil, created a seroprevalence model that incorporated a parameter for antibody decay. Using this strategy, they concluded that 75% in Manaus had been infected by October 2020.¹⁹ A later surge of infections in Manaus, however, has raised questions about model assumptions²⁰.

Ease of replication, unbiased sampling, and high-quality immunoassays—all features of national dialysis sampling—are crucial to rapid and informative seroprevalence. Nonetheless, our strategy may also have modestly underestimated SARS-CoV-2 cumulative infections for two reasons. First, SARS-CoV-2 antibodies may wane over time. Several large studies, however, including our own performed in this population, indicate that the RBD domain antibody typically persists for at least 4-6 months^{4,5}, longer than the nucleocapsid assays used in other seroprevalence studies^{16,19}. Second, our current sample underrepresents New York City, a high-risk area, perhaps contributing to a lower seroprevalence than might be otherwise expected in the Northeast region.

Our data reliably assess differences in seroprevalence by patient and community-level characteristics over time. We note the rapid spread of the infection throughout the breadth of the US. Whereas in July 2020

seroprevalence rates varied from <1 to 34%, in January 2021, nearly all sampled states had seroprevalence estimates exceeding 10% and among the four regions, the range of seroprevalence was narrow (15-21%). These trends fit with other descriptions of the pandemic, for example in Brazil, where international travel first brought the pandemic to major cities with rapid spread in densely populated areas, but eventual spread occurred throughout the country²¹.

Our estimates for case detection and infection fatality—with infection fatality exceeding 1% in the Northeast after the first wave in the Spring—match modeled estimates by Yang et al.²² The improvement in both parameters since then indicate better detection and treatment, and are generally uniformly spread throughout the US.

Strengths of our study include its unbiased sampling of hard-to-reach populations, reflective of persons most vulnerable to SARS-CoV-2, and the use of a highly specific and sensitive assay for an antibody for which data indicate a prolonged persistence in a majority of infected persons^{4,5,23}. This pragmatic approach enables rapid and repeated evaluations. The limitations include lack of data on SARS-CoV-2 rtPCR testing or COVID19 symptoms, and relative under-sampling from the Northeast region.

In summary, using unbiased data from a sentinel population, we estimate that fewer than one in four persons in the US had evidence of SARS-CoV-2 antibody in January 2021, well below the level needed to confer herd immunity. Residents of majority minority and poorer neighborhoods, and younger age groups have substantially higher prevalence of SARS-CoV-2 antibodies. Since these sub-populations overlap with persons expressing high levels of vaccine hesitancy in the US^{24,25}, vaccination campaigns will need to engage these high-risk groups in order to achieve sufficient penetration to reach community-level protection against SARS-CoV-2.

Table 1 Comparison of sampled population, US adult dialysis population, and US adult population (January 2021)

Patient characteristics	Sample population (January 2021) N=21,424		US adult dialysis population N=499,150		US adult population N=253,815,197	
	Count	%	Count	%	Count	%
Age						
18-44	2314	11	60,540	12	117,499,477	46
45-64	8635	40	207,022	41	83,892,606	33
65-79	7847	37	174,341	35	39,949,825	16
≥80	2668	12	57,247	11	12,473,289	5
Sex						
M	12,265	57	285,281	57	123,578,869	49
F	9199	43	213,869	43	130,236,328	51
Race and Ethnicity*^{&}		^{&}				
Hispanic	2945	18	87,611	18	60,861,275	19
Non-Hispanic white	6311	37	203,421	41	197,202,727	60
Non-Hispanic Black	4875	29	173,190	35	39,717,152	12
Non-Hispanic Other	2834	17	34,928	7	28,493,202	9
ZCTA Majority Race and Ethnicity*[^]⁺						
Non-Hispanic white	6481	30	206,678	41	189,968,192	58
Non-Hispanic Black	1504	7	54,999	11	12,550,083	4
Hispanic	4023	19	52,953	11	26,310,796	8
Hispanic and Black	2321	11	43,396	9	17,238,911	5
Integrated	7135	33	140,781	28	80,206,374	25
Region						
Northeast	2113	10	78,619	16	44,519,465	18
South	10857	50	214,974	43	96,250,597	38
Midwest	2055	10	94,490	19	52,876,708	21
West	6439	30	111,067	22	60,168,427	24

US adult population in 2018, US adult patients on dialysis population as of January 1 2017.

*Race, ethnicity, and ZCTA Majority Race and Ethnicity computed for total U.S. 2018 population N=326,274,356.

[&]Proportions are reported for persons with available data; 4505 (21) in the sample were missing race and ethnicity.

[^]343 and 583 people in the U.S. Renal Data System and sample populations missing data on ZCTA Majority Race/Ethnicity due to missing zip code respectively. ⁺ZCTA Majority defined as population in ZCTA ≥ 60 Hispanic, Non-Hispanic Black, or Non-Hispanic White; if in remainder ZCTAs Hispanic and Black population exceeded ≥60, ZCTA defined as 'Hispanic and Black', else as 'Other'.

Abbreviations: ZCTA-zip code tabulation area

Table 2 Seroprevalence of SARS-CoV2 antibodies in the study sample and standardized to US dialysis and US adult population in January 2021

	Unweighted sample (January 2021)		Standardized to US adult dialysis population [#]	Standardized to US adult population ^{&}	Seropositive persons per 100,000 ^Ω
	Count	Seropositive %	Seropositive %	Seropositive %	Count
Age**					
18-44	591	25.5 (23.6, 27.7)	25.5 (23.7, 27.5)	25.3 (23.3, 27.4)	23328
45-64	1824	21.1 (20.2, 22.1)	20.3 (19.4, 21.2)	19.9 (18.9, 20.8)	19861
65-79	1276	16.3 (15.4, 17.2)	15.9 (15.0, 16.7)	15.9 (15.0, 16.8)	15884
≥80	370	13.9 (12.5, 15.4)	14.1 (12.7, 15.6)	14.5 (13.1, 16.2)	14527
Sex*					
M	2250	18.3 (17.6, 19.1)	18.1 (17.4, 18.9)	20.7 (19.5, 22.0)	19934
F	1811	19.7 (18.8, 20.6)	19.3 (18.5, 20.2)	21.9 (20.5, 23.5)	21189
Race and Ethnicity**					
Hispanic	763	25.9 (24.1, 27.8)	26.2 (24.5, 27.9)	29.0 (26.2, 31.8)	15495
Non-Hispanic white	1084	17.2 (16.2, 18.2)	16.6 (15.6, 17.6)	17.6 (16.0, 19.2)	6189
Non-Hispanic Black	885	18.2 (17.0, 19.4)	18.1 (17.0, 19.3)	21.0 (18.9, 23.1)	32439
Other	374	13.2 (11.9, 14.6)	13.3 (12.0, 14.7)	17.0 (14.3, 19.7)	16315
ZCTA Majority Race/Ethnicity+**					
Hispanic	1010	25.1 (23.6, 26.4)	25.2 (23.9, 26.6)	27.4 (25.3, 29.7)	7450
Non-Hispanic white	993	15.3 (14.4, 16.3)	15.0 (14.1, 16.0)	16.4 (14.8, 18.1)	41150
Non-Hispanic Black	306	20.3 (18.3, 22.4)	20.4 (18.2, 22.6)	26.5 (22.2, 30.9)	40574
Hispanic and Black	540	23.3 (21.5, 25.0)	23.8 (22.1, 25.7)	26.4 (23.5, 29.5)	37928
Integrated	1212	17.0 (16.1, 17.9)	17.5 (16.5, 18.5)	20.8 (19.0, 22.5)	19574
Region**					
Northeast	323	15.3 (13.8, 16.8)	15.6 (14.1, 17.1)	19.0 (16.1, 21.9)	18370
South	2257	20.8 (20.0, 21.6)	21.0 (20.2, 21.8)	24.2 (22.9, 25.4)	23290
Midwest	341	16.6 (15.0, 18.2)	16.7 (15.1, 18.4)	19.9 (17.0, 22.8)	19199
West	1140	17.7 (16.7, 18.6)	17.9 (17.0, 18.9)	19.8 (18.2, 21.3)	19086
ZCTA poverty level^{###}					
<10%	776	13.3 (12.4, 14.2)	13.5 (12.6, 14.5)	15.6 (13.9, 17.5)	8135
10% to <20%	1517	18.8 (17.9, 19.6)	18.8 (17.9, 19.7)	21.0 (19.4, 22.6)	16364
20% to <30%	1101	22.7 (21.5, 23.9)	22.4 (21.1, 23.6)	26.0 (23.9, 28.2)	27489
≥30%	666	24.8 (23.2, 26.5)	23.8 (22.1, 25.5)	26.1 (23.3, 29.0)	38123
ZCTA rural or urban status					
Dense urban	3332	18.7 (18.1, 19.4)	18.5 (17.9, 19.2)	21.4 (20.3, 22.5)	17773
Metropolitan	269	16.7 (14.8, 18.8)	15.7 (14.0, 17.6)	16.8 (13.7, 19.9)	10007
Micropolitan	247	23.0 (20.3, 26.1)	21.2 (18.8, 23.9)	21.6 (17.7, 25.5)	9142
Small town or rural	205	22.0 (19.2, 25.2)	22.2 (19.4, 25.3)	25.1 (20.1, 30.0)	12196
Overall	4061	18.9 (18.3, 19.5)	18.7 (18.1, 19.2)	21.3 (20.3, 22.3)	20578

*different at $p < 0.05$, ** different at $p < 0.0001$ for the sample population. [#]Standardized to the USA dialysis population using all adults receiving dialysis for the treatment of end stage kidney disease on Jan 1st, 2017 identified through the United States Renal Data System database (N= 499,150). [&]Standardized to the U.S. population using ACS 2018 data ^ΩSeropositivity per 100,000 persons calculated as standardized count/category n X 100,000. ⁺ZCTA Majority defined if population in ZCTA ≥ 60% Hispanic, Non-Hispanic Black, or Non-Hispanic white; if in remainder ZCTAs Hispanic and Black population exceeded ≥60%, ZCTA defined as 'Hispanic and Black', else as 'Other'. Abbreviation: ZCTA-Zip code tabulation area

Figure Legends:

Figure 1: SARS-CoV-2 seroprevalence by US region in January 2021, with comparison to sampled states between July 2020

Overall seroprevalence was between 15-21% across all regions, with the highest seroprevalence in the US South. Compared to July data from patients dialyzing in the same dialysis facilities, seroprevalence was 1.8-fold (95% CI 1.5, 2.3) higher in the Northeast, 4.1-fold (95% CI 3.0, 5.7) higher in the Midwest and 4.6-fold (95% CI 3.9, 5.5) higher in the West. The largest increase in seroprevalence was observed in the South (5.1-fold (95% CI 4.5, 5.8)). All 43 states in which patients resided are listed in the figure but data are presented only for states with at least 30 persons in the January sample (n=33).

Figure 2: Case detection and infection fatality rates in January 2021, with comparison to July 2020

The detected cases per 100,000 between June-December 2020 were 23% of estimated seroprevalent persons and deaths attributed to COVID19 in January 2021 (range by region 17-30% in the Northeast and Midwest respectively). This proportion was an increase from detected cases being 14% of estimated seroprevalent persons and deaths attributed to COVID19 in July 2020 (range by region 13% to 16% in the West and Midwest respectively). The infection fatality rate in January 2021 was 0.3% (range 0.3-0.4%), compared with 0.7% in July 2020 (range 0.4-1.3%).

Funding

Ascend Clinical Laboratory funded the remainder plasma sampling.

Declaration of Interest

LC, PH, RK and PB are employed by Ascend Clinical Laboratories; MD and GB are employed by US Renal Care. GC is on the Board of Satellite Healthcare, a not-for-profit dialysis organization.

Author Contributions

SA assisted with cleaning and analysis planning, and manuscript writing. MMR developed analysis plan, supervised data analysis and contributed to manuscript writing. JH and PG undertook data cleaning and analysis, including linkage to external data and figure generation, and contributed to manuscript writing. LC and PH undertook sample processing and data preparation. GB and MD participated in study planning and sample and de-identified data provision. RK selected seroprevalence testing, supervised sample processing, and contributed to manuscript writing. PB co-conceived study, and secured seroprevalence testing. JP supervised study analysis plan, identified relevant external data, data interpretation, and supervised manuscript writing. SB assisted with data interpretation. GMC co-conceived study, supervised study analysis plan, and co-wrote manuscript.

References

1. Centers for Disease Control and Prevention. CDC COVID Data Tracker. https://covidcdc.gov/covid-data-tracker/#cases_casesper100klast7days. 2021.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020;20(5):533-534.
3. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection A Narrative Review. *Annals of Internal Medicine*. 2020;173(5):362-+.
4. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*. 2020;383(18):1724-1734.
5. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020.
6. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. *Lancet*. 2020;396(10262):1595-1606.
7. Duysburgh E, Mortgat L, Barbezange C, et al. Persistence of IgG response to SARS-CoV-2. *Lancet Infect Dis*. 2020.
8. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol*. 2020;5(52).
9. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *Lancet*. 2020.
10. U.S. Food & Drug Administration. EUA Authorized Serology Test Performance. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance>. 2020.
11. Annual Data Report. USRDS; 2018. Accessed June 15 2020.
12. U.S. Census Bureau American Community Survey. 2018 American Community Survey 5 Year Estimates, Tables B03002, S1701, and B01003. *Generated by Maria Montez-Rath; using datacensusgov; <<https://datacensus.gov/cedsci/>>; (10 July 2020)*.
13. Sisk B, Cull W, Harris JM, Rothenburger A, Olson L. National Trends of Cases of COVID-19 in Children Based on US State Health Department Data. *Pediatrics*. 2020;146(6).
14. Centers for Disease Control and Prevention. Demographic Trends of COVID-19 cases and deaths in the US reported to CDC <https://covidcdc.gov/covid-data-tracker/#demographics>. 2021; Last accessed February 6, 2021.
15. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern Med*. 2020.
16. Murhekar MV, Bhatnagar T, Selvaraju S, et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health*. 2021;9(3):e257-e266.
17. Ward H, Cooke G, Atchison C, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv*. 2020:2020.2010.2026.20219725.
18. Ward H, Atchison C, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. *medRxiv*. 2020:2020.2008.2012.20173690.
19. Buss LF, Prete CA, Jr., Abraham CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*. 2021;371(6526):288-292.
20. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet*. 2021;397(10273):452-455.

21. Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science*. 2020;369(6508):1255-1260.
22. Yang W, Kandula S, Huynh M, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. *Lancet Infect Dis*. 2021;21(2):203-212.
23. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*. 2020;53(5):925-933 e924.
24. Szilagyi PG, Thomas K, Shah MD, et al. National Trends in the US Public's Likelihood of Getting a COVID-19 Vaccine—April 1 to December 8, 2020. *JAMA*. 2020.
25. Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. *JAMA*. 2020;324(20):2095-2096.

Figure 1: SARS-CoV-2 seroprevalence by US region and sampled states in January 2021, with comparison to data from July 2020








Figure 2: Case detection and infection fatality rates in January 2021, with comparison to July 2020



Supplemental Figure 1:
 Neighborhood level characteristics associated with SARS-CoV-2 seroprevalence in January 2021, with comparisons to July 2021

